Business Leadership Series

Engage with successful business leaders who will share innovative ideas and insights into leadership styles and emerging trends.

Fall 2017 Schedule

All Business Leadership Series events will take place in Graham Memorial, Room 039 (Basement Level) from 3:00 – 4:00 pm, unless otherwise noted.

Rick Edmunds

Friday, October 6
3:00 — 4:00 pm

Richard C. Edmunds, III (Rick) is a Principal with PwC Strategy& where he leads the Strategy team within Pharma Life Sciences. He was previously Senior Vice President and Leader of the Global Healthcare Practice at Booz & Company (which became part of PwC). He is also now part of PwC’s Global Pharma & Life Sciences Leadership team. He works primarily with leading pharmaceutical and medical product companies globally and in the U.S. Mr. Edmunds’ primary areas of expertise are in corporate and business unit strategy, product and customer strategies, commercial performance improvement, organization, and mergers and acquisitions. Mr. Edmunds brings business strategy and transformation skills and a solid understanding of the health care and pharmaceutical industries. In his recent corporate strategy assignments, he has addressed the implications of changing U.S. market dynamics on pharmaceutical companies and helped define different break-out alternatives for the various lines of business. On the commercialization side, Mr. Edmunds has conducted a number of different customer strategy development efforts (including payor, physician, and consumer) and broader product strategies ranging from launch to mature/end-of-lifecycle stage. Within the context of health reform, Mr. Edmunds has worked on major cross-industry collaboration efforts that include leading pharmaceutical companies, major national health plans, and PBMs.

Mr. Edmunds has written numerous articles related to the changing pharmaceutical landscape, new commercial approaches, organizing to win, and alternative strategic approaches. Most recently he has been a lead writer for Beyond 2020: Building Strategic Coherence in the New Health Economy published in PharmaExecutive and related articles in Managed Healthcare Executive and Strategy & Business.

Mr. Edmunds joined Booz Allen Hamilton/Booz & Company/Strategy& in 2005 after nearly 13 years at McKinsey & Co., where he worked as part of their Pharma/Medical Product Leadership Group. He holds an MBA from the Darden Graduate School of Business Administration at the University of Virginia, where he received both the Shermet Award and the Faculty Award for Academic Excellence in 1992. He holds a BA in economics from the University of North Carolina.

He was formerly Chairman of the Washington Tennis and Education Foundation, Is Vic Chair for Darden’s Corporate Advisory Board and is an Ex-Officio member of the Board of Trustees.,. He has a wife and two children and lives in Alexandria, Virginia.

Rajiv Maluste

Thursday, October 12
7:00 — 8:00 pm

Dr Rajiv G. Maluste has a doctorate in Economic History from the London School of Economics, a Masters in Public Policy from Princeton University and a MBA from Rutgers University.  Rajiv’s previous professional background has been in capital markets for two decades where he gained rich experiences from working in London, New York and Asia.  He was an Executive Director with Morgan Stanley New York and London where he focused on emerging markets and international capital flows.  Rajiv has also worked as an economist for the US Government’s Department of the Treasury in Washington, working with the IMF.  Rajiv launched his independent consultancy in 2011.  His current academic and consulting portfolio includes several UK universities and Study Abroad Programs in London.

Spring 2017 Schedule

Lisa Church

Friday, February 3
3:00 — 4:00 pm

Lisa Church is the president of eMarketer, a research firm located in New York City that provides business information on digital media, marketing, and commerce.  Since joining the organization in 2007, Church has developed strong, lasting relationships with many of the world’s largest brands, media companies, and agencies.  eMarketer has helped these companies implement better marketing practices, improve performance, and adapt to rapid changes in technology, media, and consumer behavior.  A market leading authority, eMarketer has more than quintupled in size under Church’s leadership.  Her current focus is in scaling eMarketer to broaden international and market segment expansion, enhancing the client experience, and sustaining top quality in an environment of aggressive growth.  eMarketer was sold to Axel Springer in July, 2016.

Prior to joining eMarketer, Church spent more than twenty years leading high-growth technology companies to positions of market dominance. The senior Vice President of marketing at Advent Software (ADVS) from 1983-1995, she helped the company grow from a start-up to a market leader in portfolio trading, accounting and performance measurement for investment management firms, hedge funds, prime brokers, and banks; her experience culminated in an Advent IPO offering.

Following her time at Advent, Church became the Vice President of North American operations at Decalog and later served as the chief executive officer at Compliance Tools.  In both roles, she helped large multinational investmenst banks and trading houses implement global trading, accounting, and compliance technology for straight through processing.  Under her direction, Decalog quadrupled run rate revenue within two years while significantly growing operating margins and was subsequently sold to SunGard.  Similarly, Compliance Tools was sold to Wolters Kluwer in 2001.

Church serves on several boards, including VIETRI, Inc., the Advertising Council, the International Board of Advisors for Carolina Performing Arts, and the Board of Advisors for the School of Media and Journalism at UNC-Chapel Hill.  She was recently selected for induction into the North Carolina Media and Journalism Hall of Fame.

A Carolina alumna, Church earned a B.A. in International studies from UNC in 1976 and an MBA in 1979.  She divides her time between Chapel Hill and New York City and has two grown sons and a daughter in law who also reside in New York.

Ashley Moore Remmers

Friday, February 24
3:00 — 4:00 pm

Ashley is primarily involved in the management and oversight of client relationships and new business development.  She is also a resource for clients with closely-held businesses.  She joined Diversified Trust in 2000 to launch its private equity strategy and has served on the Board of Directors since 2004.  Previously, Ashley spent twenty two years at SSM Corporation as an Officer and Owner. At SSM, she served as financial advisor to individual and corporate clients in the areas of acquisitions, divestitures, and joint ventures. During her latter years at SSM, Ashley focused on making direct investments for SSM Venture Partners, a private equity firm.

She received a Bachelor of Arts in Economics cum laude and graduated Phi Beta Kappa from the University of North Carolina at Chapel Hill. She received a Master of Business Administration from the Harvard Business School. Ashley is a member of the Board of Directors of Orgill, Inc., the Memphis Symphony Orchestra, and the Hope Christian Community Foundation.  She also serves as Vice-Chairman of the Memphis Regional Advisory Board of Teach for America.  She is a member of the Council of Advisors for St. Mary’s Episcopal School, the Women’s Leadership Council at the University of North Carolina, and the Estate Planning Council of Memphis.

Fall 2016 Schedule

Robbie Huffines

Friday, September 23
4:00 — 5:00 pmRobert Huffines

Mr. Huffines joined J.P. Morgan in 1991 and is currently a Vice Chairman of Investment Banking. Mr. Huffines joined J.P. Morgan in the Mergers and Acquisitions group where he was healthcare focused. From 2002 – 2010, Mr. Huffines was co-head of the global healthcare investment banking group. In 2011, he was promoted to Vice Chairman to deepen the firm’s relationships with significant clients.

Mr. Huffines has advised numerous healthcare companies on strategic transactions, including: Medivation’s sale to Pfizer (pending); Alere’s sale to Abbott (pending); Baxter on Baxalta’s sale to Shire; Celgene1s acquisition of Receptos; Merck’s acquisition of Cubist; Boston Scientific1s acquisition of Endo’s Men’s Health business; Johnson &Johnson’s sale of Cordis and Ortho Clinical Diagnostics; Thermo Fisher’s acquisition of FEI Affymetrix and Life Technologies; Baxter’s acquisition of Gambro; Healthpoint’s sale to Smith & Nephew; Lincare’s sale to the Linde Group; Amgen acquisition of Mustafa Ncvzat; Kinetic Concepts’ go-private; Sanofi-Avcntis’ acquisition of Genzyme; Merck’s acquisition of Schering Plough; Eli Lilly’s acquisition of ChemGen; BristolMyers Squibb’s acquisition of Medarex; Celgene’s acquisition of Phannion, Kinetic Concept’s acquisition of LifeCell; Amgen’s sale of Amgen K.K. to Takeda; Eisai’s acquisition of MGI Pharmaceuticals; Takeda on its division and integration of the Takeda Abbott Products joint venture; Sirtris Pharmaceutical’s sale to Glaxo SmithKline; Guidant’s sale to Boston Scientific and Abbott; Merck’s acquisitions of Banyu Pharmaceuticals; Rosetta Inpharmatics and Pro Vantage Healthcare and divestiture of Medco Health Solutions; Bristol-Myers Squibb’s divestitures of Medical Imaging; Zimmer and Mead Johnson; and acquisition of DuPont Pharmaceuticals; L’Oreal (a significant owner of Sanofi) on the Sanofi-Aventis merger; Guidant’s acquisition of CardioThoracic Systems and Cook (withdrawn); Sofamor Danek’s sale to Medtronic; Oratec’s sale to Smith & Nephew; Johnson & Johnson’s acquisitions of Mitek, Cordis and Neutrogena, and divestiture of Janssen Animal Health; Fujisawa’s sale of its multisource pharmaceutical business.

Mr. Huffines’ equity offering experience includes offerings for Baxalta, Q\1intiles, Thermo Electron, Ironwood, Celgene, Bristol-Myers, Mead Johnson, Wyeth, Mylan, Medco Health Solutions, Kinetic Concepts, Zimmer, Guidant, Sofamor Danek, Volcano, and Medtronic. Fixed income transaction experience includes offerings for Eli Lilly, Merck, Celgene, Amgen, Bristol Myers Squibb, Johnson & Johnson, Wyeth, Pfizer, Guidant, Baxter, Medco Health Solutions Thermo Electron, and Quest.

Prior to joining J.P. Morgan, Mr. Huffines worked at Alex Brown & Sons, specializing in equity financings and advisory assignments for emerging growth companies. Mr. Huffines has an M.B.A. from the University of Virginia, where he received the faculty award for academic excellence. He has a B.A. from the University of North Carolina, where he majored in English and Economics. Mr. Huffines is married and has four children. His volunteer work includes The Brookings/Gates Global Health Innovative Financing Advisory Group, the Student Sponsor Partnership, a member of the Corporate Advisory Board at the Darden School, a member of the Entrepreneurial Committee at the University of North Carolina and serving as a board member of the Spence School and Solid Biosciences.


Past Speakers

Peter Boneparth

Chair of Audit Committee for the Board, Jet Blue Airways


Audrey Boone Tillman, Esq.

Executive VP and General Counsel, Aflac Incorporated


Thomas “Tucker” York, Jr.

Global Head of Private Wealth Management, Goldman Sachs


Sallie Krawcheck

CEO and Co-founder, Ellevest